MEI reports 90% ORR in Phase Ib of ME-401 in hematologic malignancies

MEI Pharma Inc. (NASDAQ:MEIP) reported updated data from 30 evaluable patients with relapsed or refractory follicular lymphoma or chronic

Read the full 195 word article

User Sign In